Immunogen (IMGN) Tops Q4 EPS by 26c, Offers Q1 Guidance
Get Alerts IMGN Hot Sheet
Price: $31.25 --0%
Revenue Growth %: -100.0%
Financial Fact:
Loss from operations: -38.84M
Today's EPS Names:
FRSB, DGICA, UXIN, More
Revenue Growth %: -100.0%
Financial Fact:
Loss from operations: -38.84M
Today's EPS Names:
FRSB, DGICA, UXIN, More
Join SI Premium – FREE
Immunogen (NASDAQ: IMGN) reported Q4 EPS of $0.16, $0.26 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $85.8 million versus the consensus estimate of $37.09 million.
GUIDANCE:
Immunogen sees Q1 2021 revenue of $65-75 million, versus the consensus of $53.1 million.
- operating expenses between $200 million and $210 million; and
- cash and cash equivalents at December 31, 2021 to be between $140 million and $150 million.
For earnings history and earnings-related data on Immunogen (IMGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Gilead Sciences (GILD) Misses Q1 EPS by 288c
- SPS Commerce (SPSC) Tops Q1 EPS by 12c
- Arca Biopharma (ABIO) Reports Q1 Loss of $0.14
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!